BACKGROUND: Glutathione peroxidase 1 (GPx1) is an antioxidant selenoenzyme that protects the cells against reactive oxygen species. Its activity depends on the concentration of selenium (Se) which is present in the active centre of the enzyme. The genetic polymorphism of GPx1 encoding gene (GPx1) associated with the proline (Pro) to leucine (Leu) change at codon 198 is supposed to be functional. An in vitro study performed on human breast carcinoma cell line showed that GPx1Leu allele was associated with a lower responsiveness of the enzyme to Se added to the culture medium. Some authors observed a decrease in GPx1 activity associated with GPx1 Leu allele in humans; however, there were no findings on how GPx1 activity changes with Se concentration in individuals with different GPx1 genotypes. AIM OF THE STUDY: To assess whether GPx1 activity that depends on the Se status may be influenced by GPx1 polymorphism through studying this relationship in the blood of healthy individuals. METHODS: The association between the Se status, GPx1 activity and GPx1 genotype was assessed in 405 individuals of Polish origin. GPx1 activity in red blood cells was measured by the spectrophotometric method by Paglia and Valentine, using t-butylhydroperoxide as the substrate. Plasma Se concentration was measured using graphite furnace atomic absorption spectrometry. GPx1 Pro198Leu polymorphism was determined with the Molecular Beacon Real-Time PCR assay. RESULTS: In the subjects examined, the mean plasma Se concentration was 54.4 +/- 14.2 mcg/L. The mean GPx1 activity was 15.1 +/- 4.7 U/g Hb. No difference regarding both the parameters was found between individuals with different GPx1 genotype. However, the association between GPx1 activity and Se concentration, analyzed separately for each genotype group, was not the same. The correlation coefficients amounted to r = 0.44 (p < 0.001) for Pro/Pro, r = 0.35 (p < 0.001) for Pro/Leu and r = 0.25 (p = 0.45) for Leu/Leu group, which indicates that the correlation strength was as follows: Pro/Pro > Pro/Leu > Leu/Leu. Notably, statistically significant difference in this relationship (analyzed as difference between correlation coefficients for linear trends) was found between genotypes Pro/Pro and Leu/Leu (p = 0.034). CONCLUSIONS: The findings of the present study provide evidence for the hypothesis based on in vitro studies which assumes that GPx1 Pro198Leu polymorphism has a functional significance for the human organism and that this functionality is associated with a different response of GPx1 activity to Se. They also point to the importance of the genetic background in the assessment of the Se status with the use of selenoprotein biomarkers such as GPx1 activity.
BACKGROUND:Glutathione peroxidase 1 (GPx1) is an antioxidant selenoenzyme that protects the cells against reactive oxygen species. Its activity depends on the concentration of selenium (Se) which is present in the active centre of the enzyme. The genetic polymorphism of GPx1 encoding gene (GPx1) associated with the proline (Pro) to leucine (Leu) change at codon 198 is supposed to be functional. An in vitro study performed on humanbreast carcinoma cell line showed that GPx1Leu allele was associated with a lower responsiveness of the enzyme to Se added to the culture medium. Some authors observed a decrease in GPx1 activity associated with GPx1Leu allele in humans; however, there were no findings on how GPx1 activity changes with Se concentration in individuals with different GPx1 genotypes. AIM OF THE STUDY: To assess whether GPx1 activity that depends on the Se status may be influenced by GPx1 polymorphism through studying this relationship in the blood of healthy individuals. METHODS: The association between the Se status, GPx1 activity and GPx1 genotype was assessed in 405 individuals of Polish origin. GPx1 activity in red blood cells was measured by the spectrophotometric method by Paglia and Valentine, using t-butylhydroperoxide as the substrate. Plasma Se concentration was measured using graphite furnace atomic absorption spectrometry. GPx1 Pro198Leu polymorphism was determined with the Molecular Beacon Real-Time PCR assay. RESULTS: In the subjects examined, the mean plasma Se concentration was 54.4 +/- 14.2 mcg/L. The mean GPx1 activity was 15.1 +/- 4.7 U/g Hb. No difference regarding both the parameters was found between individuals with different GPx1 genotype. However, the association between GPx1 activity and Se concentration, analyzed separately for each genotype group, was not the same. The correlation coefficients amounted to r = 0.44 (p < 0.001) for Pro/Pro, r = 0.35 (p < 0.001) for Pro/Leu and r = 0.25 (p = 0.45) for Leu/Leu group, which indicates that the correlation strength was as follows: Pro/Pro > Pro/Leu > Leu/Leu. Notably, statistically significant difference in this relationship (analyzed as difference between correlation coefficients for linear trends) was found between genotypes Pro/Pro and Leu/Leu (p = 0.034). CONCLUSIONS: The findings of the present study provide evidence for the hypothesis based on in vitro studies which assumes that GPx1 Pro198Leu polymorphism has a functional significance for the human organism and that this functionality is associated with a different response of GPx1 activity to Se. They also point to the importance of the genetic background in the assessment of the Se status with the use of selenoprotein biomarkers such as GPx1 activity.
Authors: Ole Raaschou-Nielsen; Mette Sørensen; Rikke D Hansen; Kirsten Frederiksen; Anne Tjønneland; Kim Overvad; Ulla Vogel Journal: Cancer Lett Date: 2006-06-23 Impact factor: 8.679
Authors: D Ratnasinghe; J A Tangrea; M R Andersen; M J Barrett; J Virtamo; P R Taylor; D Albanes Journal: Cancer Res Date: 2000-11-15 Impact factor: 12.701
Authors: Gitte Ravn-Haren; Anja Olsen; Anne Tjønneland; Lars O Dragsted; Bjørn A Nexø; Håkan Wallin; Kim Overvad; Ole Raaschou-Nielsen; Ulla Vogel Journal: Carcinogenesis Date: 2005-11-14 Impact factor: 4.944
Authors: C R de Farias; B R Cardoso; G M B de Oliveira; I C de Mello Guazzelli; R M Catarino; M C Chammas; S M F Cozzolino; M Knobel Journal: J Endocrinol Invest Date: 2015-04-17 Impact factor: 4.256
Authors: F Häuser; H Rossmann; D Laubert-Reh; P S Wild; T Zeller; C Müller; S Neuwirth; S Blankenberg; K J Lackner Journal: Genes Immun Date: 2015-09-10 Impact factor: 2.676
Authors: Marija Bošković; Tomaž Vovk; Marko Saje; Katja Goričar; Vita Dolžan; Blanka Kores Plesničar; Iztok Grabnar Journal: Neurochem Res Date: 2012-12-02 Impact factor: 3.996
Authors: Ewa Jablonska; Jolanta Gromadzinska; Beata Peplonska; Wojciech Fendler; Edyta Reszka; Magdalena B Krol; Edyta Wieczorek; Agnieszka Bukowska; Peter Gresner; Michal Galicki; Oskar Zambrano Quispe; Zbigniew Morawiec; Wojciech Wasowicz Journal: BMC Cancer Date: 2015-10-07 Impact factor: 4.430
Authors: Jian Gong; Li Hsu; Tabitha Harrison; Irena B King; Stefan Stürup; Xiaoling Song; David Duggan; Yan Liu; Carolyn Hutter; Stephen J Chanock; Charles B Eaton; James R Marshall; Ulrike Peters Journal: Nutrients Date: 2013-05-21 Impact factor: 5.717
Authors: Catherine Méplan; Lars Ove Dragsted; Gitte Ravn-Haren; Anne Tjønneland; Ulla Vogel; John Hesketh Journal: PLoS One Date: 2013-09-10 Impact factor: 3.240